Sepiapterin Reductase Inhibition Leading to Selective Reduction of Inflammatory Joint Pain in Mice and Increased Urinary Sepiapterin Levels in Humans and Mice.
Masahide FujitaDébora da Luz SchefferBruna Lenfers TurnesShane J F CroninAlban LatrémolièreMichael CostiganClifford J WoolfAlexandra LatiniNick A AndrewsPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2019)
SPR inhibition reduces the pain associated with joint inflammation, thus showing its potential utility as an analgesic strategy for inflammatory joint pain. In addition, SPR inhibition increases urinary sepiapterin levels, indicating the potential of this measurement as a noninvasive biomarker of target engagement of SPR inhibitors, such as sulfasalazine, a disease-modifying antirheumatic drug that is currently used as a first-line treatment for rheumatoid arthritis.
Keyphrases
- chronic pain
- rheumatoid arthritis
- neuropathic pain
- pain management
- oxidative stress
- spinal cord injury
- emergency department
- spinal cord
- social media
- risk assessment
- disease activity
- type diabetes
- systemic sclerosis
- climate change
- ankylosing spondylitis
- interstitial lung disease
- metabolic syndrome
- rheumatoid arthritis patients
- human health
- adipose tissue
- insulin resistance